secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001437749-26-001194
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics prelim FY2025 global rev ~$616M; 2026 guided $875-900M
----------------------------------------------------------------------

- Preliminary FY2025 total global revenue ~$616M; U.S. BRIUMVI net product rev Q4 ~$182M, FY ~$594M.
- 2026 target total global revenue $875-900M; U.S. BRIUMVI net product rev $825-850M.
- 2026 operating expense target ~$350M (excl. SBC) + ~$100M for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up.
- Pipeline milestones: ENHANCE IV BRIUMVI trial data mid-2026; subcutaneous BRIUMVI topline year-end 2026/1Q 2027; azer-cel Phase 1 data in Progressive MS H2 2026.
- Plans to commence registration-directed trial for BRIUMVI outside MS and additional exploratory studies in autoimmune disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926001194/0001437749-26-001194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926001194/tgtx20260113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-001194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer